Skip to content

MAZE MAZE Free cash flow yield

Free cash flow yield at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
3.3%+2.2pp
Septerna, Inc. logo
Septerna, Inc.SEPN
12.3%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
19.2%+13.6pp
Olema Pharmaceuticals, Inc. logo
Olema Pharmaceuticals, Inc.OLMA
-24.3%
Zymeworks logo
ZymeworksZYME
-4.1%-1.5pp
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
-16.6%-0.6pp

Other financials

Income statement

See full
Revenue$20.0M
Operating income-$26.6M+25.0%
Net income-$24.2M+26.2%
EPS (diluted)-$0.45+60.9%

Balance sheet

See full
Cash & equivalents$198.8M-32.5%
Total debt$61.2M+137%
Total equity$341.7M+17.0%
Total assets$419.7M+26.1%

Cash flow

See full
Operating cash flow-$39.1M-32.5%
CapEx$93.0K-68.9%
Free cash flow-$39.2M-31.5%

Valuation

See full
Market cap$1.48B
Enterprise value$1.34B
P/S7.9×

Profitability

See full
Operating margin-71.5%
Net margin-65.4%
FCF margin-65.1%

Returns & leverage

See full
Return on equity-38.7%
Debt / equity0.2×+0.1×
Current ratio17.9×+1.8×

Where this comes from

Calculated from MAZE’s reported figures.

Based on trailing twelve months.

The official record: MAZE’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about MAZE's free cash flow yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MAZE's free cash flow yield?
MAZE (MAZE) reported free cash flow yield of -8.3% in Q1 2026.
What does free cash flow yield mean?
Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.